Search Results for: PDGFRB

84 interactions involving PDGFRB - platelet derived growth factor receptor beta found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
SOCS1 suppressor of cytokine signaling 1
  • Interleukin-7 signaling
  • Regulation of KIT signaling
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Interleukin-4 and Interleukin-13 signaling
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
PDGFB platelet derived growth factor subunit B
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Non-integrin membrane-ECM interactions
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Pegpleranib
  • Malignant pleural mesothelioma
  • Glioma
PTPN1 protein tyrosine phosphatase non-receptor type 1
  • Integrin signaling
  • Negative regulation of MET activity
  • Regulation of IFNG signaling
  • PTK6 Down-Regulation
  • MECP2 regulates neuronal receptors and channels
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
  • 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
  • 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
  • [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
  • {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
  • Compound 19
  • 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
  • 2-(Oxalyl-Amino)-Benzoic Acid
  • {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
  • Novo Nordisk a/S Compound
  • N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
  • 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • PNU177836
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
  • (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
  • 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
  • L-cysteic acid
  • 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
  • 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
  • Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
  • 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
  • 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
  • [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
  • {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
  • N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
  • 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
  • ISIS 113715
  • Trodusquemine
  • Ertiprotafib
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
  • [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
  • 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
  • [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
  • 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
  • 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
  • 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
  • 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
  • N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
  • [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
  • 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
  • ISOTHIAZOLIDINONE ANALOG
  • 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
  • p-Benzoyl-L-phenylalanine
  • 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
  • (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
  • 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
  • (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
CEP76 centrosomal protein 76
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
GRB10 growth factor receptor bound protein 10
  • Signaling by SCF-KIT
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • RET signaling
  • FLT3 Signaling
  • Response of EIF2AK1 (HRI) to heme deficiency
NCK2 NCK adaptor protein 2
  • Downstream signal transduction
  • Nephrin family interactions
  • Ephrin signaling
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • Regulation of cortical dendrite branching
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
GRB7 growth factor receptor bound protein 7
  • GRB7 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signal transduction
  • Tie2 Signaling
  • RET signaling
NEDD4 NEDD4 E3 ubiquitin protein ligase
  • ISG15 antiviral mechanism
  • Downregulation of ERBB4 signaling
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Antigen processing: Ubiquitination & Proteasome degradation
PTPRJ protein tyrosine phosphatase receptor type J
  • Phosphorylation of CD3 and TCR zeta chains
  • Neutrophil degranulation
  • Negative regulation of MET activity
  • Negative regulation of FLT3
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Negative regulation of FLT3
  • ATP
  • Dasatinib
  • XL228
  • K-00546
  • Fostamatinib
COPB1 COPI coat complex subunit beta 1
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
FGFR1 fibroblast growth factor receptor 1
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 in disease
  • Signaling by plasma membrane FGFR1 fusions
  • Palifermin
  • Sorafenib
  • Heparin
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • XL999
  • 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
  • (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
  • 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Selpercatinib
  • Pralsetinib
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
  • Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD)
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
PRDX2 peroxiredoxin 2
  • Detoxification of Reactive Oxygen Species
  • TP53 Regulates Metabolic Genes
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • 3-sulfino-L-alanine
  • N-Carbamoyl-Alanine
  • Copper
S1PR1 sphingosine-1-phosphate receptor 1
  • Lysosphingolipid and LPA receptors
  • Interleukin-4 and Interleukin-13 signaling
  • Potential therapeutics for SARS
  • Fingolimod
  • Asfotase alfa
  • Siponimod
  • Ozanimod
CAV3 caveolin 3
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Caveolinopathies, including: Limb-girdle muscular dystrophy (LGMD) 1C; Rippling muscle disease (RMD); Idiopathic hyperCKemia; Distal myopathy with decreased caveolin 3; Hypertrophic cardiomyopathy (HCM)
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
  • Limb-girdle muscular dystrophy (LGMD)
COPA COPI coat complex subunit alpha
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2
  • ISG15 antiviral mechanism
  • Inhibition of PKR
  • Fostamatinib

Page 3 out of 5 pages